Post-Coronavirus Warnings From EU Pharma Industry
Need To Ensure IP & Manufacturing Relaxations Are Temporary
Speakers at a recent COVID-19 webinar discussed a number of issues related to the pandemic, including intellectual property protections, matching supply with demand, and what to do about excess manufacturing capacity once the crisis is over.
You may also be interested in...
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
Having acquired Xiidra from Novartis and getting US approval of Miebo in 2023, B+L’s two-product dry eye franchise delivered 66% year-over-year growth during Q4 2023.